Heartseed

IPO

Cardiac regeneration through iPSC cell therapy

Tokyo, Japan · Founded 2015 · $77.6M raised

Headquarters
Tokyo
Employees
11–50
Founded
2015
Business Model
B2B
Total Funding
$77.6M
Last Round
$14.6M Series DMay 2023
Rounds
3

About

Heartseed (Tokyo: 219A.T) is a Japanese biotechnology company focused on the research and development of iPSC (induced pluripotent stem cell)-based cardiac regeneration therapies for patients with severe heart failure. Founded in 2015 as a spinout from Keio University, the company develops cardiomyocyte spheroids that can supplement damaged heart muscle tissue. Heartseed completed an IPO on the Tokyo Stock Exchange on July 30, 2024, having raised over $84 million across seven funding rounds, with investors including SMBC Venture Capital and Keio Innovation Initiative.

Summary

Heartseed is a Biotech company based in Tokyo, Japan, founded in 2015. It has raised $77.6M in total across 3 rounds, most recently a $14.6M Series D round in May 2023. Investors include SMBC Venture Capital, Astellas Venture Management and UTokyo Innovation Platform.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJul 2024
$10.1M

Sign up to see all 4 rounds

Series B through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Heartseed on Indexed.vc
<a href="https://indexed.vc/companies/heartseed"><img src="https://indexed.vc/api/badge/company/heartseed" alt="Heartseed on Indexed.vc" width="260" height="76" /></a>